Related Experiment Videos
State of the art in cholesterol management: targeting multiple pathways
1Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, USA.
Insights
Lowering low-density lipoprotein (LDL) cholesterol reduces heart disease risk. New selective inhibitors, like ezetimibe, show promise alone or with statins for better LDL cholesterol management.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Elevated low-density lipoprotein (LDL) cholesterol is a major risk factor for coronary heart disease (CHD).
- Statins are primary agents for lowering LDL cholesterol and reducing CHD mortality, but alternative strategies are explored.
Purpose of the Study:
- To review alternative and additional treatment strategies for lowering LDL cholesterol beyond statins.
- To evaluate the potential of selective cholesterol absorption inhibitors, such as ezetimibe, in managing LDL cholesterol levels.
Main Methods:
- Review of existing literature on cholesterol absorption inhibitors (bile acid sequestrants, cholesterol absorption blockers, plant stanols).
- Discussion of the mechanisms, limitations, and therapeutic potential of various LDL-lowering agents.
- Focus on the development and application of selective cholesterol inhibitors like ezetimibe.
Main Results:
- Nonspecific intestinal cholesterol absorption inhibitors reduce liver cholesterol and increase LDL receptors but have limited efficacy due to tolerability and compensatory liver effects.
- Selective cholesterol inhibitors offer a targeted approach to lowering LDL cholesterol.
- Ezetimibe demonstrates potential for both monotherapy and combination therapy to improve LDL cholesterol reduction.
Conclusions:
- Combining statins with agents that target cholesterol absorption and synthesis may offer maximal therapeutic benefit.
- Selective cholesterol inhibitors like ezetimibe represent a significant advancement in LDL cholesterol management strategies.
Abstract:
The relationship between increased serum levels of total cholesterol and increased risk of coronary heart disease (CHD) is widely accepted, as is the corollary that lowering elevated levels of low-density lipoprotein (LDL) cholesterol, a significant risk factor, reduces CHD mortality. Although statins are the most widely used agents to lower LDL cholesterol levels and demonstrate significant clinical benefits, alternate and/or additional treatment strategies are also being studied. One such approach for which several classes of agents are available is the nonspecific inhibition of intestinal cholesterol and bile acid absorption. Although all of these inhibitors-which include bile acid sequestrants, cholesterol absorption blockers, and plant stanols-reduce cholesterol concentrations within liver cells and increase the expression of LDL receptors, they are limited in their effectiveness because of poor tolerability and compensatory effects by the liver that blunt their ability to lower LDL. Ideally, the combination of a statin and another agent that specifically targets cholesterol absorption and promotes excretion while simultaneously decreasing synthesis may provide the greatest therapeutic benefit. The recent development of selective cholesterol inhibitors, including ezetimibe, provides an approach to lowering LDL that has significant potential both as monotherapy and in combination therapy.